{"id":"https://openalex.org/W2271086433","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.9500","title":"Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors.","display_name":"Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2271086433","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.9500","mag":"2271086433"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.9500","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.9500","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.9500","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113716990","display_name":"Victor M. Santana","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V. M. Santana","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077260725","display_name":"Sharyn D. Baker","orcid":"https://orcid.org/0000-0003-3062-3252","observed_orcids":["https://orcid.org/0000-0003-3062-3252"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. D. Baker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027333697","display_name":"Beth M. McCarville","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. McCarville","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043293908","display_name":"Clinton F. Stewart","orcid":"https://orcid.org/0000-0002-1546-9720","observed_orcids":["https://orcid.org/0000-0002-1546-9720"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. F. Stewart","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060308592","display_name":"Jianrong Wu","orcid":"https://orcid.org/0000-0002-3519-5894","observed_orcids":["https://orcid.org/0000-0002-3519-5894","https://orcid.org/0000-0003-2395-4619","https://orcid.org/0000-0002-5598-0478"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048193615","display_name":"Catherine A. Billups","orcid":"https://orcid.org/0000-0003-2819-4946","observed_orcids":["https://orcid.org/0000-0003-2819-4946"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Billups","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059541221","display_name":"Sheri L. Spunt","orcid":"https://orcid.org/0000-0002-1669-2676","observed_orcids":["https://orcid.org/0000-0002-1669-2676"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. L. Spunt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034374604","display_name":"Wayne Lee Furman","orcid":"https://orcid.org/0000-0001-7352-3556","observed_orcids":["https://orcid.org/0000-0001-7352-3556"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. L. Furman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110197815","display_name":"Lisa M. McGregor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. M. McGregor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062018101","display_name":"Shangying Hu","orcid":"https://orcid.org/0000-0002-4778-1612","observed_orcids":["https://orcid.org/0000-0002-4778-1612"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Hu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039997334","display_name":"John Carl Panetta","orcid":"https://orcid.org/0000-0003-1308-7208","observed_orcids":["https://orcid.org/0000-0003-1308-7208"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. C. Panetta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080224930","display_name":"Wilburn E. Reddick","orcid":"https://orcid.org/0000-0002-1054-1201","observed_orcids":["https://orcid.org/0000-0002-1054-1201"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. E. Reddick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063456712","display_name":"Andrew M. Davidoff","orcid":"https://orcid.org/0000-0001-7900-2794","observed_orcids":["https://orcid.org/0000-0001-7900-2794"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Davidoff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103612582","display_name":"W. H. Leung","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. H. Leung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5045180889","display_name":"Fariba Navid","orcid":"https://orcid.org/0000-0002-7916-6382","observed_orcids":["https://orcid.org/0000-0002-7916-6382"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Navid","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"9500","last_page":"9500"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12278","display_name":"Vascular Tumors and Angiosarcomas","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11469","display_name":"Lymphatic System and Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":1.0},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.9300000071525574},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.6899999976158142},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.6039999723434448},{"id":"https://openalex.org/keywords/pdgf-receptor-beta","display_name":"PDGF receptor beta","score":0.7229999899864197},{"id":"https://openalex.org/keywords/vegfr2","display_name":"VEGFR2","score":0.9599999785423279},{"id":"https://openalex.org/keywords/refractory-solid-tumors","display_name":"refractory solid tumors","score":0.8230000138282776},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8550000190734863},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8240000009536743},{"id":"https://openalex.org/keywords/rhabdoid-tumor","display_name":"rhabdoid tumor","score":0.7680000066757202},{"id":"https://openalex.org/keywords/rhabdomyosarcoma","display_name":"rhabdomyosarcoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/medulloblastoma","display_name":"medulloblastoma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/synovial-sarcoma","display_name":"synovial sarcoma","score":0.9909999966621399}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9106223583221436},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.826224684715271},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.754550576210022},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.698739767074585},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.547304093837738},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4861147403717041},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.47437602281570435},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4647936224937439},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.43331676721572876},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4201829433441162},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.4110445976257324},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4100356101989746},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3604699373245239},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2818177342414856},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.22391220927238464},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.10230118036270142}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.9500","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.9500","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.9500","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2891334381","https://openalex.org/W3018854574","https://openalex.org/W2140172669","https://openalex.org/W4281486962","https://openalex.org/W2059545683","https://openalex.org/W1978670801","https://openalex.org/W4246345261","https://openalex.org/W2539438153","https://openalex.org/W2272627972","https://openalex.org/W2263367667"],"abstract_inverted_index":{"9500":[0],"Background:":[1],"Angiogenesis":[2],"is":[3,274],"necessary":[4],"for":[5],"tumor":[6,172],"growth,":[7],"metastasis,":[8],"and":[9,13,26,40,52,59,78,83,101,130,154,163,183,206,219,231,238,246,266],"survival.":[10],"Endothelial":[11],"cells":[12,61],"pericytes,":[14],"key":[15],"cellular":[16],"components":[17],"of":[18,43,68,81,85,91,119,141,166,279],"blood":[19],"vessels,":[20],"are":[21,256],"primarily":[22],"regulated":[23],"by":[24,49],"VEGF":[25,56],"PDGF":[27],"signaling.":[28],"We":[29,96],"therefore":[30],"performed":[31],"a":[32,117],"phase":[33,253],"I":[34],"trial":[35],"to":[36,46,104],"determine":[37],"the":[38,143,207,222],"feasibility":[39],"toxicity":[41],"profile":[42],"agents":[44],"combined":[45],"inhibit":[47],"angiogenesis":[48],"targeting":[50],"PDGFR-\u03b2":[51],"VEGFR2":[53],"with":[54,57,62,72,276],"sorafenib,":[55,257],"bevacizumab,":[58,261],"endothelial":[60],"continuous":[63],"low-dose":[64],"CYC.":[65],"Methods:":[66],"Cohorts":[67],"3-6":[69],"eligible":[70],"patients":[71,109,169,193],"recurrent":[73],"solid":[74],"tumors":[75],"received":[76,116,331],"CYC":[77,199,332],"escalating":[79],"dosages":[80],"sorafenib":[82],"then":[84],"bevacizumab":[86],"(see":[87],"table).":[88],"Each":[89],"course":[90,135,300],"therapy":[92],"was":[93,201,211],"21":[94],"days.":[95],"used":[97],"standard":[98],"physical":[99],"exams":[100],"laboratory":[102],"tests":[103],"assess":[105],"toxicities.":[106],"Results:":[107],"19":[108],"(11":[110],"males;":[111],"median":[112,118,196,225],"age,":[113],"9.2":[114],"years)":[115],"4":[120,307],"courses":[121,140],"(range,":[122],"1-23).":[123],"The":[124,195,251],"table":[125],"summarizes":[126],"dose":[127],"levels":[128],"explored":[129],"dose-limiting":[131],"toxicities":[132,147,160],"(DLTs)":[133],"in":[134],"1.":[136],"With":[137],"additional":[138],"71":[139],"therapy,":[142],"most":[144],"common":[145],"nonhematologic":[146],"\u2265":[148],"grade":[149],"3":[150,302,312,320,327],"included":[151],"rashes":[152],"(5)":[153],"febrile":[155],"neutropenia":[156,162],"(2).":[157],"Predominant":[158],"hematologic":[159],"were":[161],"lymphopenia.":[164],"Five":[165],"17":[167],"evaluable":[168],"had":[170,185],"partial":[171],"responses":[173],"(2":[174],"rhabdoid,":[175],"1":[176,178,180,301,318,325],"rhabdomyosarcoma,":[177],"medulloblastoma,":[179],"synovial":[181],"sarcoma),":[182],"9":[184],"disease":[186],"stabilization.":[187],"First-dose":[188],"pharmacokinetics":[189],"results":[190],"from":[191],"14":[192],"follow.":[194],"(range)":[197,226],"apparent":[198],"clearance":[200],"2.03":[202],"L/hr/m2":[203],"(1.8-2.1":[204],"L/hr/m2),":[205],"absorption":[208],"rate":[209],"constant":[210],"0.12":[212],"hr-1":[213],"(0.08-0.23":[214],"hr-1).":[215],"Sorafenib":[216,288],"at":[217],"90":[218,258,303,316,323],"110":[220,308],"mg/m2yielded":[221],"following":[223],"respective":[224],"values:":[227],"Cmax,":[228],"1.1":[229],"(0.37-2.4)":[230],"1.6":[232],"(0.91-2.4)":[233],"mg/L;":[234],"Tmax,":[235],"8.5":[236],"(3.9-17.5)":[237],"10.7":[239],"(8.2-14.1)":[240],"h;":[241],"AUC":[242],"(0-12h),":[243],"10.4":[244],"(2.6-23.0)":[245],"13.6":[247],"(8.0-20.4)":[248],"mg*h/L.":[249],"Conclusions:":[250],"recommended":[252],"II":[254],"doses":[255],"mg/m2/dose":[259],"BID;":[260],"15":[262,324],"mg/kg":[263],"q3":[264,295],"weeks;":[265],"CYC,":[267],"50":[268],"mg/m2":[269],"once":[270,336],"daily.":[271,337],"This":[272],"regimen":[273],"feasible":[275],"promising":[277],"evidence":[278],"anti-tumor":[280],"activity":[281],"that":[282],"warrants":[283],"further":[284],"investigation.":[285],"No.":[286,297],"pts*":[287],"(mg/m2)":[289],"PO":[290,335],"BID":[291],"Bevacizumab":[292],"(mg/kg)":[293],"IV":[294],"wks":[296],"DLT":[298,299],"5":[304,309],"0":[305],"None":[306],"2":[310],"Grd":[311,319,326],"rash,":[313,328],"\u2191lipase":[314],"6":[315,322],"10":[317],"thrombus":[321],"anorexia":[329],"*All":[330],"(50":[333],"mg/m2)":[334]},"counts_by_year":[{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2016-06-24T00:00:00"}